Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Covance collaborates with UK hospital on early clinical research

Says agreement will provide quicker access to patients for phase I trials

- PMLiVE

NICE consults on what makes good social care

Citizens Council gives views as UK agency prepares to expand its remit

- PMLiVE

BMS hires Roche’s Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

- PMLiVE

India’s patents versus India’s patients

What the Roche Pegasys case means for big pharma

Guidance published encouraging NHS to adopt social media

Social media is central to the effectiveness of the NHS, says NHS Employers organisation.

- PMLiVE

FDA fast tracks two new lung cancer drugs

Boehringer’s afatinib and Roche/Astellas’ Tarveca receive accelerated review process

UK outlines pipedream of a paperless health service

Health secretary issues empty 'challenge' for NHS to make better use of IT

- PMLiVE

UK inactivity on value-based pricing plan damaging, say MPs

Health Committee report also highlights needs to address end of the cancer drugs fund

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links